
April 14, 2025
Invion (ASX:IVX) is a clinical-stage Australian life sciences company pioneering the next generation of photodynamic therapy (PDT) for the treatment of cancer and infectious diseases. Invion is advancing a transformative approach to disease treatment and diagnosis with a platform grounded in preclinical promise and growing clinical validation.
At the core of Invion’s platform is Photosoft, a proprietary suite of next-generation photosensitizers that selectively accumulate in diseased cells. Upon light activation, these compounds trigger a targeted oxidative stress response, leading to cell death with high precision. Unlike traditional PDT agents, Photosoft compounds are engineered to overcome the limitations of toxicity, off-target damage, and limited immune engagement. They are designed to deliver enhanced safety, selectivity, immune system activation, and theragnostic capabilities.
Invion is strategically expanding its clinical and commercial footprint through non-dilutive global partnerships that accelerate development while preserving shareholder value. In South Korea, Hanlim Pharm is fully funding the preclinical development of Photosoft for two high-need indications: glioblastoma multiforme (GBM) — one of the most aggressive and treatment-resistant brain cancers — and oesophageal cancer. Under the terms of the partnership, Hanlim covers all development costs, while Invion retains full ownership of the underlying intellectual property, positioning the company to benefit from future global opportunities.
Company Highlights
- Clinical-stage Pipeline in Multiple Indications: Successfully completed Phase II prostate cancer trial, ongoing Phase I/II skin cancer trial, and anogenital cancer trial initiating in 2025. Multiple cancer and infectious disease programs underway.
- Photosoft Platform Technology: Combines cancer selectivity, immune system activation, and minimal toxicity. Preclinical studies show INV043 can regress multiple cancers, deliver superior safety and efficacy and improve tumour control to 80 percent in combination therapy studies with blockbuster ICIs (vs 12 percent with ICIs alone).
- Renowned Partners & Global Pharma-funded Collaborations: Working with distinguished research institutions like Peter MacCallum Cancer Centre and Hudson Institute of Medical Research. Further, Hanlim Pharm (GBM, oesophageal cancer) and Dr.inB (HPV) are funding multiple programs without requiring Invion to contribute capital or give up IP.
- Theragnostic Capability: Photosoft compounds enable both treatment and imaging, allowing for highly precise cancer targeting and enhanced surgical decision-making.
- Strong Clinical and IP Foundation: GMP-grade INV043 manufactured and patented in Australia, with global IP protection extending to at least 2041.
- Compelling Upside: Following a share consolidation and reduced overhangs, IVX offers significant re-rating potential with multiple clinical readouts expected over the next six to 12 months.
This Invion profile is part of a paid investor education campaign.*
Click here to connect with Invion (ASX:IVX) to receive an Investor Presentation
IVX:AU
Sign up to get your FREE
Invion Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
The Conversation (0)
10 April
Invion Limited
Sign up to get your FREE
Invion Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases
18h
Funded Collaboration Agreement with Protect Animal Health
Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
09 October
Repayment of Lind Facility with Successful Capital Raise
Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
07 October
Trading Halt
Invion Limited (IVX:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
27 August
Appendix 4E and Annual Report
Invion Limited (IVX:AU) has announced Appendix 4E and Annual ReportDownload the PDF here. Keep Reading...
20 August
Orphan Drug Designation Granted by U.S. FDA for Anal Cancer
Invion Limited (IVX:AU) has announced Orphan Drug Designation Granted by U.S. FDA For Anal CancerDownload the PDF here. Keep Reading...
23 September
5 Biggest Pharma Stocks in 2025
The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent... Keep Reading...
08 September
Seegnal Inc. Announces Extension of Maccabi Health Services Contract
Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded... Keep Reading...
03 September
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results
All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...
28 August
Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds
Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing,... Keep Reading...
20 August
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results
All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...
Latest News
Sign up to get your FREE
Invion Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00